When Pancreatitis on Mounjaro (tirzepatide for T2D) Becomes a Reason to Stop

What does the Mounjaro label say about stopping?

The pancreatitis warning begins with the observation that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been seen with GLP-1 receptor agonists or Mounjaro [1].

The label then tells clinicians to observe patients carefully after starting Mounjaro for signs and symptoms of acute pancreatitis: persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting [1]. If pancreatitis is suspected, the label says to discontinue Mounjaro and initiate appropriate management [1].

That is the whole stop instruction. It is built on suspicion rather than on a confirmed diagnosis [1].

Does a lipase level or severity grade decide when to stop?

The pancreatitis warning gives no lipase cutoff and does not grade pancreatitis as mild, moderately severe or severe [1]. It does not vary its instruction by severity: hemorrhagic and necrotizing pancreatitis are named among the cases observed, and the action is the same [1].

Can tirzepatide be restarted after pancreatitis?

The Mounjaro label text gives no instruction on whether or when treatment can be restarted after pancreatitis is suspected [1].

How often does pancreatitis happen with tirzepatide?

A systematic review and meta-analysis of nine randomized trials with 9,871 participants (6,828 on tirzepatide and 3,043 controls) found no significant increase in pancreatitis with tirzepatide compared with placebo, basal insulin or selective GLP-1 receptor agonists (RR 1.46, 95% CI 0.59 to 3.61) [2]. A separate meta-analysis across multiple GLP-1 receptor agonists, including tirzepatide, found no difference in pancreatitis between the drug groups and controls [3]. A narrative review of real-world evidence also found no clear increase in severe events such as pancreatitis with GLP-1 receptor agonist weight-loss therapies [4].

These are group estimates from trials and observational data. The label instruction applies to an individual with symptoms that suggest pancreatitis [1].